An interventional study of Colovac and Stoma Creation in Colorectal Cancer, Rectal Cancer and Rectal Tumor, sponsored by SafeHeal Inc. Terminated at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by SafeHeal Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 781 studies in Rectal Neoplasms with a site in United States — 80 open to participants now, 141 under way, 9 of them phase 3. Rectal Neoplasms · United States.
Among the 781 studies in Rectal Neoplasms with a site in United States, this one is the 457th largest by enrollment of the 620 interventional ones that give a count, is one of 33 that started in 2022, is one of 149 with no phase, and was the 677th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →80 of the 781 studies in Rectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18–100
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
781 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 236 · Phase 2 302 · Phase 3 63 · Phase 4 3
First in 1990; this study’s year is marked. 33 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 39 across the 620 interventional studies, 150 across the 98 observational. Of the 585 that completed or were terminated, 184 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
106 of 781 have an industry lead sponsor. The 10 most frequent:
SafeHeal Inc is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
SafeHeal Inc has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
48 of the studies in Rectal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02008656Memorial Sloan Kettering Cancer CenterTrial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management | 2026-11 |
| NCT02403505Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairEarly Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer | 2026-11-28 |
| NCT04165772Memorial Sloan Kettering Cancer CenterStudy of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | 2026-11-30 |
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
Add all 48 to your calendar (.ics) → With an account.
Among the 781 studies in Rectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized trial to assess the safety and effectiveness of the Colovac in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer.
A primary diverting stoma is widely used by surgeons in order to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which means that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit.
Colovac is a local, temporary, minimally invasive bypass device that provides protection of the anastomosis and safely postpones stoma creation for 10 days after surgery. By postponing stoma creation for 10 days, Colovac is designed to avoid stoma creation in all patients except those patients whose anastomoses have not healed by 10 days after surgery, allowing the others to return to normal activity more quickly and safely.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
This study's enrollment of 18 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Browse Rectal Neoplasms studies →SafeHeal Inc is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Compared within Rectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results. including, but not limited to:
Occurrence of any of the following during the colorectal surgery:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive Colovac during colorectal surgery
Device: Colovac
Patients receive the standard of care, a protective stoma, during colorectal surgery
Procedure: Stoma Creation
A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
Protective ileostomy
Avoidance of Ostomy
Reduction in stoma creation rate
Time frame: 12 Months
Safety Major Complications
Rate of subjects with major complications
Time frame: 12 Months
| Milestone | Colovac | Standard of Care |
|---|---|---|
| Started | 10 | 8 |
| Completed | 8 | 6 |
| Not completed | 2 | 2 |
Reduction in stoma creation rate
| Participants | Colovac | Standard of Care |
|---|---|---|
| Avoidance of Ostomy | 7 | 0 |
Rate of subjects with major complications
| Participants | Colovac | Standard of Care |
|---|---|---|
| Safety Major Complications | 3 | 2 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | 1/8 (12.5%) | 7/8 (87.5%) | 6/8 (75%) |
| Colovac | 0/10 (0%) | 6/10 (60%) | 7/10 (70%) |
| Event | Standard of Care | Colovac |
|---|---|---|
| Anastomosis LeakageGeneral disorders | 2/8 | 4/10 |
| General state of deterioration with dehydration, resulting in deathGeneral disorders | 1/8 | 0/10 |
| Undernutrition with Naso Gastric TubeGastrointestinal disorders | 1/8 | 0/10 |
| IleusGastrointestinal disorders | 1/8 | 0/10 |
| InfectionInfections and infestations | 1/8 | 0/10 |
| Urinary Tract InfectionInfections and infestations | 1/8 | 0/10 |
| CRP ElevationInfections and infestations | 1/8 | 0/10 |
| Dehydration which resolvedGeneral disorders | 1/8 | 0/10 |
| Colon IntussusceptionGastrointestinal disorders | 0/8 | 1/10 |
| Acute Renal FailureRenal and urinary disorders | 0/8 | 1/10 |
| Event | Standard of Care | Colovac |
|---|---|---|
| Nausea/vomitingGastrointestinal disorders | 1/8 | 2/10 |
| Abdominal/ Anal painGastrointestinal disorders | 1/8 | 1/10 |
| CholestasisGastrointestinal disorders | 1/8 | 0/10 |
| DiarrheaGastrointestinal disorders | 1/8 | 1/10 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/8 | 0/10 |
| Heart FailureCardiac disorders | 1/8 | 0/10 |
| IleusGastrointestinal disorders | 1/8 | 1/10 |
| Infection of incision/surgery wound on left sideSurgical and medical procedures | 1/8 | 0/10 |
| Other - Epigastric PainGastrointestinal disorders | 1/8 | 0/10 |
| Other - Lymphopenia to XelodaBlood and lymphatic system disorders | 1/8 | 0/10 |
| Age, Continuous(years) | Colovac | Standard of Care | Total |
|---|---|---|---|
| Mean | 67.1 ± 10.9 | 60.9 ± 11.4 | 64.3 ± 11.3 |
| Sex: Female, Male(Participants) | Colovac | Standard of Care | Total |
|---|---|---|---|
| Female | 6 | 3 | 9 |
| Male | 4 | 5 | 9 |
| Race and Ethnicity Not Collected(Participants) | Colovac | Standard of Care | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Mean Body Mass Index(kg/m^2) | Colovac | Standard of Care | Total |
|---|---|---|---|
| Mean | 24.8 ± 5.5 | 25.7 ± 4.8 | 25.2 ± 5.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Jan 2024, 24 months.
Results were first posted in Jul 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SafeHeal Inc